Harnessing neoantigen-specific T cells for precision cancer immunotherapy
👉 @NatRevClinOncol, Jan 2024, free access link at https://t.co/PNnpM5Uzfp
💬 about "Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers" @YosephRami
Cytotoxic CD4+ tumor-infiltrating lymphocytes (TILs) in the cover of @CCR_AACR (October 1st, 2023)
⚡️The work of our post-doc @AriannaDraghi featured
Full article available at 👉https://t.co/klEGmOpkTH
Commentary by @DrBetofMDPhD and @jasonlukemd 👉https://t.co/GPe3MvQ5G6
**Acquired resistance to #melanoma Immunotherapy**
Approx. 30% of patients with #melanoma who initially respond to #Immunotherapy later progress. Knowledge of molecular mechanisms helps develop new treatments for this major challenge in #oncology
** #PDL1 status in metastatic #melanoma**
- @EMA_News approved #Opdualag (#relatlimab plus #nivolumab) only for patients whose tumors express low PD-L1 https://t.co/pOAKvi7s5M
- @US_FDA approved regardless of PD-L1
https://t.co/aJoxe7LSaT
more at https://t.co/J3CAm8G9hW